Sir,
Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to choroidal osteoma

Choroidal osteoma is a rare osseous benign tumour typically occurring in otherwise healthy young women.¹ Although benign, this tumour may lead to

severe visual loss by subretinal fluid and haemorrhage associated with choroidal neovascularization (CNV).

We report a case of CNV associated with choroidal osteoma for which intravitreal ranibizumab permitted significant improvement in the regression of macula oedema and CNV.

Figure 1 Fundus photographs of the left eye before and 6 months after the treatment (a and b), macular OCTs of the left eye before and 6 months after the treatment (c and d), early venous phase of fluorescein angiographs of the left eye before and 6 months after the treatment (e and f), and late phase of fluorescein angiographs of the left eye before and 6 months after the treatment (g and h). Fundus photograph showed choroidal osteoma with subretinal haemorrhage at parafoveal area, suggesting the presence of CNV (arrowhead). At 6 months after the intravitreal ranibizumab injection, fundus photograph showed resolution of subretinal haemorrhage. Macular OCT showed subretinal fluid (between arrows), suggesting the presence of CNV. At 6 months after the intravitreal ranibizumab injection, macular OCT showed complete resolution of CNV and subretinal fluid. (e and g) In early venous (e) and late phase of fluorescein angiography (g), leakage confirmed CNV (arrowheads). (f and h) At 6 months after intravitreal ranibizumab injection, early venous (f) and late phase of fluorescein angiography (h) showed cessation of leakage.

Case report

A 43-year-old woman had a subfoveal choroidal osteoma, sized four disc diameter, in her left eye. Best-corrected visual acuity (BCVA) was 20/20 in her right eye and 20/32 in her left eye. Ultrasonography and computed tomography showed an echodense mass.

On follow-up 4 years later, BCVA was decreased to 20/200 in her left eye and the mass showed subfoveal haemorrhage, suggesting the presence of CNV (Figure 1a). Optical coherence tomography (OCT) (Figure 1c) and early and late phase of fluorescein angiography (Figure 1e and g) confirmed the presence of classic CNV. The risks and benefits of the intravitreal injection of ranibizumab were explained to the patient and an informed consent was obtained. An intravitreal injection of 0.5 mg of ranibizumab was given. Six months after the treatment, subretinal haemorrhage resolved in fundus photograph (Figure 1b). OCT showed resolution of subretinal fluid (Figure 1d) and fluorescein angiography revealed cessation of leakage (Figure 1f and h). BCVA was increased to 20/100.

Comment

The reasons for vision loss from choroidal osteoma include CNV, subfoveal fluid, and photoreceptor degeneration. The cause of CNV development is unknown. But it has been hypothesized that the thinned, degenerated retinal pigment epithelium overlying the osteoma allows the growth of new blood vessels.¹

Several treatments are tried but with limited success. Laser photocoagulation of CNV associated with choroidal osteoma was less effective owing to depigmentation of RPE that often reduces the absorption of laser energy.¹ The surgical removal of subfoveal CNV has been performed successfully, but the visual result has been poor.² Recently, PDT and transpupillary thermotherapy have been tried, but the visual result was also poor.^{3–4} Intravitreal bevacizumab was carried out and improvement of visual acuity and regression of CNV was observed.⁵ Ranibizumab has recently been used successfully for the treatment of CNV secondary to age-related macular degeneration.⁶

We used intravitreal ranibizumab for the treatment of CNV secondary to choroidal osteoma, and observed regression of CNV and recovery of visual acuity. This is the first report of ranibizumab for treating CNV related to choroidal osteoma. We propose that intravitreal ranibizumab may be a useful treatment in CNV secondary to choroidal osteoma. Long-term follow-up and further studies are required to confirm the role of intravitreal ranibizumab in CNV.

References

- Shields CL, Shields JA, Augsburger JJ. Choroidal osteoma. *Surv Ophthalmol* 1988; **33**: 17–27.
- Foster BS, Fernadez-Suntay JP, Dryja TP, Jakobiec FA, D'Amico DJ. Surgical removal and histopathologic findings of subfoveal neovascular membrane associated with choroidal osteoma. *Arch Ophthalmol* 2003; **121**: 273–276.
- Parodi MB, Da Pozzo S, Saviano S, Ravalico G. Photodynamic therapy for choroidal neovascularization associated with choroidal osteoma. *Retina* 2001; **21**: 660–661.
- Shukla D, Tanawade RG, Ramasamy K. Transpupillary thermotherapy for subfoveal choroidal neovascular membrane in choroidal osteoma. *Eye* 2006; **20**: 845–847.
- Ahmadi H, Vafi N. Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). *Graefes Arch Clin Exp Ophthalmol* 2007; **245**: 1731–1733.
- Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR; MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. *Arch Ophthalmol*. 2007; **125**: 1460–1469.

M-h Song and Y-j Roh

Department of Ophthalmology, St Mary's Hospital,
Catholic university of Korea, Seoul, Korea
E-mail: youngjungroh@hanmail.net

Eye (2009) **23**, 1745–1746; doi:10.1038/eye.2008.313;
published online 24 October 2008

Sir, Irrigation of the capsular bag using a sealed-capsule irrigation device and 5-fluorouracil

This is the first reported case of cataract surgery where the empty capsular bag is sealed with PerfectCapsule® (Milvella Limited) and then irrigated with 5-fluorouracil (5-FU) for 3 min using a concentration of 50 mg/ml.¹ A hydrophilic acrylic intraocular lens (IOL; Bausch & Lomb (B&L) Akreos Adapt) was implanted into the capsular bag. The surgery and follow-up for 1 year have been uneventful. The lens capsule centrally and peripherally remains very clear.

Case report

A 63-year-old woman underwent right cataract surgery with a hydrophilic acrylic IOL ((B&L Akreos Adapt) implanted into the capsular bag. The capsulorhexis was 4.0 mm diameter. Before the implantation of IOL, and at the conclusion of irrigation/aspiration, PerfectCapsule was inserted into the anterior chamber filled with Provisc (Alcon Laboratories) and located over the capsulorhexis.² Suction through a syringe was applied, and the seal was tested for integrity using balanced salt with fluorescein. With the completion of sealing, 10 ml of 5-FU in a concentration of 50 mg/ml was irrigated through the capsular bag. The solution of 5-FU was stained with fluorescein to detect any leakage. After irrigation for 3 min with 5-FU, the capsular bag was flushed with 2 ml of balanced salt. The suction was then released and PerfectCapsule removed from the anterior capsule by simply pulling on the external tubing. The capsular bag was then filled with OVD and the B&L Akreos Adapt IOL inserted, using an injector, into the capsular bag. The entire procedure was uneventful.

The visual acuity is 20/20 corrected (−1.25 DS). The endothelial cell count postoperatively shows little